论文部分内容阅读
目的:分析吉西他滨与长春瑞滨分别联合顺铂治疗晚期乳腺癌的近期疗效及不良反应。方法:2013年11月至2015年12月间,我院将90例乳腺癌晚期患者通过电脑随机分组的方式,分为治疗组和常规组,各45例。常规组采用吉西他滨联合顺铂治疗,而治疗组给予长春瑞滨联合顺铂治疗。对比分析两组患者的不良反应和治疗效果。结果:治疗组总有效率为84.44%(38/45);常规组总有效率为77.78%(35/45),且治疗组不良反应发生率为8.89%(4/45);常规组不良反应发生率为6.67%(3/45),无论是治疗效果还是不良反应两组间比较差异不显著(P>0.05)。结论:在对晚期乳腺癌患者进行治疗期间,无论采用吉西他滨联合顺铂治疗还是长春瑞滨联合顺铂治疗均能够对病情起到一定的控制作用,且两种药物的不良反应较低,可广泛使用。
Objective: To analyze the short-term efficacy and side effects of gemcitabine combined with vinorelbine plus cisplatin in the treatment of advanced breast cancer. Methods: Between November 2013 and December 2015, 90 patients with advanced breast cancer were randomly divided into treatment group and conventional group, with 45 cases in each group. The conventional group was treated with gemcitabine combined with cisplatin, while the treatment group was given vinorelbine combined with cisplatin. The adverse reaction and treatment effect of two groups were compared. Results: The total effective rate was 84.44% (38/45) in the treatment group, 77.78% (35/45) in the conventional group and 8.89% (4/45) in the treatment group. The adverse reactions in the conventional group The incidence rate was 6.67% (3/45). No significant difference was found between the two groups (P> 0.05). Conclusions: During the treatment of patients with advanced breast cancer, either gemcitabine combined with cisplatin or vinorelbine combined with cisplatin can play a role in the disease control, and the adverse reactions of the two drugs are low and widely available use.